No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Free Fatty Acid Receptor 1 (FFAR1) market is a subset of the Endocrine and Metabolic Disorders Drugs market. FFAR1 is a G-protein coupled receptor that is involved in the regulation of glucose and lipid metabolism. It is a potential target for the development of novel therapeutics for metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
FFAR1 agonists are being developed by a number of pharmaceutical companies, including Novo Nordisk, Merck, and Sanofi. Other companies in the market include Boehringer Ingelheim, AstraZeneca, and Eli Lilly. Additionally, several biotechnology companies are developing FFAR1 agonists, such as Amgen, Gilead Sciences, and GlaxoSmithKline. Show Less Read more
